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A best evidence topic in surgery was written according to a structured protocol. The question addressed
whether LINX™ Reﬂux management system is an efﬁcacious treatment for patients with symptoms of
gastro-oesophageal reﬂux disease (GORD) not controlled by proton pump inhibitors (PPI). Forty-eight
LINX-related papers were identiﬁed using the reported search, of which three represented the best
evidence to answer the clinical question. The authors, journal, date and country of publication, patient
group, study type, relevant outcomes and results of these papers are tabulated. All three studies were
prospective case studies. They demonstrated that LINX is an efﬁcacious treatment for GORD patients
with good short and medium term outcomes and an acceptable safety proﬁle. Further studies are
required to determine its long term outcomes and its relative efﬁcacy as compared to other established
treatments.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The LINX® Reﬂux Management System (Torax Medical, Inc.,
Shoreview, MN, USA) is a newly-licensed surgical treatment for
GORD. It is a magnetic device that aims to augment the lower
oesophageal sphincter without altering hiatal anatomy [1]. The
Best Bets approach is a validated, concise and systematic method of
collecting and appraising evidence to answer clinically relevant
questions for which evidence is scarce, and has been fully described
in a previous publication by the International Journal of Surgery
(IJS) [2]. Brieﬂy, it is a mini-review, constructed around a clinical
scenario, involving a systematic search and standardised assess-
ment of tabulated outcomemeasures, concluding with a discussion
and clinical bottom line. In order to review the evidence base for
the efﬁcacy of LINX in GORD, a best evidence topic was constructed
according to the recognised protocol.
2. Clinical scenario
You are in upper gastrointestinal surgery outpatients reviewing
a 31 year old female with severe reﬂux symptoms despite high-
dose PPI treatment. She has had no previous upper abdominal
surgery, and her investigations have revealed uncomplicated GORD.
by Elsevier Ltd. All rights reservedwithout hiatus hernia. She asks you whether LINX would be a
suitable option for her.
3. Three part question
In patients with GORD, does LINX give good symptomatic relief?
4. Search strategy
A standardised literature search was performed on the Medline
database (Medline 1948 to April 2014 using OVID interface). The
search terms were as follows: (((LINX) OR MSA) OR sphincter de-
vice) AND (((reﬂux) OR GERD) OR GORD). The search was limited to
English papers to include case series, randomized and non-
randomized clinical trials, comparative studies and systematic re-
views. In addition, reference lists of selected papers were searched.
The search was current as of 25th April 2014.
5. Search outcome
Two hundred and thirty nine abstracts were identiﬁed using the
reported search, which were appraised independently by two au-
thors. Of these, only 44 were related to the LINX reﬂux manage-
ment system. Thirty six papers were irrelevant, two were reviews.
Of the remaining six papers, three provided longer follow up data.
Table 1
Three papers reporting most recent data from case series of LINX patients.
Author, date
and country
Study type and
level of evidencea
Patient group Outcomes Key results Comments
Bonavina L, Saino G,
Bona D, Sironi A,
Lazzari V; Dec 2013;
Italy [5]
Prospective
case series,
level II-3
100 consecutive
LINX patients
from single centre
Length of follow up:
Median 3 years
(range 368d to
6 years)
Oesophageal
pH:
Median % time pH < 4: 8%
reduced to 3.2% (p < 0.001)
Normalisation of oesophageal
acid exposure or 50%
reduction: 80% of patients
This is a large single-centre
study, which reports good
outcomes at a median of three
years.
Thirty of these patients are also
included in Lipham's analysis
[6].
Removals of LINX in this cohort
occurred a considerable time
after insertion (up to 771 days),
so there is a possibility that
there will be additional future
removals in this cohort with
longer follow up.
Quality
of life:
Median GERD-HRQLb score:
16 on PPIs and 24 off PPIs at
baseline, improved to 2
(p < 0.001)
50% reduction (improvement)
in score: 93% of patients
PPI use: % of patients: 100% at baseline,
reduced to 15%
Adverse
outcomes:
3 removals
1) 378 days post implant for
persistent odynophagia; Dor
fundoplication performed
immediately after removal
2) 771 days post implant for
continued GORD symptoms;
Toupet fundoplication
immediately after removal
3) 406 days post implant for
persistent dysphagia unre-
sponsive to oesophageal
dilation; immediate recon-
struction of angle of His with
Lortat-Jacob antireﬂux
procedure
2 oesophageal dilations post
implant
1) 5 days after, for dysphagia
and odynophagia
2) 335 days after, for dysphagia
4 mild chest pain/odynophagia
that improved within four
months
3 had increased belching that
did not require treatment
Lipham JC, DeMeester TR,
Ganz RA, Bonavina L,
Saino G, Dunn DH,
Fockens P, Bemelman W.
Mar 2012, USA. [6]
Prospective
case series,
level II-3
44 patients from
four study centres
in US and Europe
Length of follow up:
Median 3.7 years
(range 119-1827d)
Oesophageal
pH:
Mean % time pH < 4: 11.9%
reduced to 3.8% at three years
Normalisation of oesophageal
acid exposure:
80% achieving normalization;
p < 0.001
This study includes patients
from a four study centres,
which is encouraging for the
generalisability of its good
results.
It has the smallest sample size
of the three studies.
Again, removals occurred late
(up to 1302 days post
insertion), which may herald a
future high incidence of late
removal of LINX.
50% reduction
(improvement)
in score:
100% of patients
Mean GERD-HRQLb score: 25.7
at baseline, improved to 3.3
reduction in pH.
PPI use: % of patients: 100% at baseline,
reduced to 20%
Adverse effects: Dysphagia in 43%, all resolved
by 3 months
3 removals
1) At 226 days for dysphagia;
Nissen fundoplication at
later date
2) At 468 days, for MRI evalu-
ation of unrelated neuro-
logical symptoms
3) At 1302 days for continued
GORD symptoms; Nissen
fundoplication
(continued on next page)
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Table 1 (continued )
Author, date
and country
Study type and
level of evidencea
Patient group Outcomes Key results Comments
Ganz RA, Peters JH, Horgan S,
Bemelman WA,
Dunst CM,
Edmundowicz SA,
Lipham JC, Luketich JD,
Melvin WS,
Oelschlager BK, Schlack-
Haerer SC,
Smith CD, Smith CC,
Dunn D,
Taiganides PA.
Feb 2013, USA [1]
Prospective
case series,
level II-3
100 patients from
thirteen centres in
the US and one in
the Netherlands
Length of follow up:
3 years, but
oesophageal
pH data only
available
at 1 year
Oesophageal pH: Normalisation of oesophageal
acid exposure or 50%
reduction:
64% of patients at one year
This is a multi-centre study
across thirteen centres. The
follow-up time in this study is
three years, and follow up for
oesophageal pH is only one
year.
In this paper, no erosions or
migrations of the LINX device
were reported.
Quality of life: Patients having 50% reduction
(improvement) in GERD-HRQLb
score: 92%
PPI use: % of patients: 13% at 3 years
Adverse effects 68% described dysphagia post-
surgery, 4% at 3 years
6 removals
1) 21 days after for persistent
dysphagia
2) 31 days after for persistent
dysphagia
3) 93 days after for persistent
dysphagia
4) 489 days after for persistent
reﬂux symptoms
5) 1062 days after for persis-
tent chest pain
Grade A oesophagitis devel-
oped in 3 in 1 year, 4 at 2 years
Grade D oesophagitis devel-
oped in 1 in 1 year
2 patients had inability to belch
or vomit at 3 years
a US Preventive Services Task Force (USPSTF) classiﬁcation used.
b HRQL ¼ Health-related Quality of Life.
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Three papers reporting most recent data from case series of LINX
patients were selected as representing the best evidence to answer
the question (see Table 1).
6. Discussion
Current treatment for GORD consists of two main options: long-
term medical acid suppression therapy or a surgical anti-reﬂux
procedure. Proton pump inhibitors can be effective with an excel-
lent safety proﬁle, however up to 40% of patients fail medical
management due to intolerance of medication or lack of efﬁcacy
[3]. Risks with PPIs also include B12 vitamin deﬁciency, Clostridium
difﬁcile infection, community-acquired pneumonia and osteopo-
rosis [3]. Anti-reﬂux surgery, consisting of cruroplasty in cases of
hiatus hernia followed by fundoplication to reinforce the lower
oesophageal sphincter, has good medium-term effects and in most
patients obviates the needs for long-term anti-reﬂux medication.
There is however no standardised technique to fundoplicationwith
a variety of techniques described with respect to the extent and
position of wrap. In addition, traditional anti-reﬂux surgery has a
number of side effects including recurrent symptoms (31%),
dysphagia (4%) and gas bloat syndrome (4%) [4]. The LINX system
was developed to provide a permanent solution to GORD by aug-
menting the sphincter barrier with a simple laparoscopic proce-
dure. The LINX device is comprised of an expandable ring of linked
magnetic beads which may be placed around the lower oesoph-
agus. The LINX device does not alter gastric anatomy and augments
the physiologic barrier to reﬂux. As a standardized and quick pro-
cedure, it should result in consistent clinical outcomes. However, as
yet there is no long-term follow-up data on patients with LINXdevices, and in particular some uncertainty regarding the ease with
which the device may be removed in the long term should this be
necessary.
The best evidence regarding LINX for GORD comprises three
prospective case-series studies [1,5,6]. In each, patients served as
their own control, with each individual's baseline data compared
with that collected at various time intervals post-implant. Two
studies were funded in part by Torax Medical, the manufacturer of
the LINX device, and all three studies had at least one author who
was a contemporaneous or previous consultant for Torax Medical.
Patient selection was guided by manufacturer's labelling and was
broadly the same for each study: patients were between 18 and 75
years of age, BMI <35, with at least a 6-month history of reﬂux
disease, persistent symptoms despite daily PPI and reﬂux
conﬁrmed with oesophageal pH monitoring. Patients were
excluded if they had a hiatus hernia >3 cm, erosive oesophagitis
grade C or D (Los Angeles classiﬁcation), allergies to the materials
used or Barrett's oesophagus. The main outcomes measured by all
three studies were change in oesophageal pH, use of PPIs and
quality of life as measured by the GORD Health Related Quality of
Life score. Safety and adverse events were also documented.
Overall taking into account the fact that thirty patients were
duplicated in two datasets [5,6], the three papers document a total
of 214 cases, with median follow-up of 3e3.7 years. Median time
taken to ﬁt the device (not including port placement and removal)
ranged from 36 to 47 min. Seventy percent of patients ﬁtted with
LINX achieved normalisation or more than 50% reduction in oeso-
phageal acid exposure. Complete cessation of proton-pump inhib-
itor use occurred in 85% of patients. GORD Health Related Quality of
Life score improved by at least 50% in 91% of patients. No study
reported erosion or migration of LINX; however, 12 devices were
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tients, persistent symptoms in four, need for MRI in one, odyno-
phagia in one and vomiting of unknown cause in one. Operations to
remove LINX occurred between 21 and 1062 days post-
implantation, and eight patients went on to have a further anti-
reﬂux procedure.
One key limitation of the studies is that they had very strict
exclusion criteria. Hence the efﬁcacy of LINX has not been
demonstrated in the obese, those with a large hiatus hernia, those
with a component of oesophageal dysmotility and those that have
previously undergone gastric surgery (eg anti-reﬂux or bariatric
procedures). It is also important to recognize that all studies
comprising best evidence on this topic were authored and/or fun-
ded by Torax Medical, the manufacturer of LINX, which may result
in bias toward positive results. Although all three study method-
ologies included pre-operative oesophageal manometry, post-
operative motility outcomes were not reported: such investiga-
tion in subsequent studies would help in understanding how LINX
works and whether it is more likely to fail in patients with some
degree of pre-existing dysmotility.
Another important limitation is that median length of follow up
is in the region of three years, which means that we do not know
the longer-term incidence of device removal and the need for redo
surgery. It may be pertinent to draw parallels between the LINX
device and the Angelchik prosthetic ring, a popular surgical device
used to treat GORD in the 1980s. These were doughnut-like-shaped
prostheses made of an elastomer shell ﬁlled with a silicone gel,
attached with a silicone marking strap that permits ring closure
and radiographic localization. Initially this was an effective option,
however long-term studies demonstrated complications including
outﬂow obstruction, disruption, migration, erosion, pericapsular
ﬁbrosis, failure to control gastro-oesophageal reﬂux, and down-
ward slippage of the prosthesis [7] with reoperation required in
5e15% of cases [8]. Conversely, it may be noted that given the
relative novelty of the LINX, there may well be an improvement in
outcomes over time as surgeons overcome their learning curve and
becomemore familiar with the technique. Finally the only evidence
regarding LINX is at present from case series and as such we do not
have to date any data on the relative efﬁcacy of LINX as compared to
conventional anti-reﬂux surgery.
7. Clinical bottom line
LINX is an efﬁcacious treatment for GORD patients with good
short and medium term outcomes and an acceptable safety proﬁle.
Further studies are required to determine its long term outcomesand its relative efﬁcacy as compared to other established
treatments.
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